Deferred Tax Assets, Operating Loss Carryforwards of Can-Fite BioPharma Ltd. from 31 Dec 2018 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Can-Fite BioPharma Ltd. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 31 Dec 2018 to 31 Dec 2024.
  • Can-Fite BioPharma Ltd. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Dec 2024 was $26,998,000, a 5.4% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Can-Fite BioPharma Ltd. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $26,998,000 +$1,392,000 +5.4% 31 Dec 2024 20-F 14 Apr 2025 2024 FY
Q4 2023 $25,606,000 +$469,000 +1.9% 31 Dec 2023 20-F 14 Apr 2025 2024 FY
Q4 2022 $25,137,000 -$1,211,000 -4.6% 31 Dec 2022 20-F 28 Mar 2024 2023 FY
Q4 2021 $26,348,000 -$5,964,000 -18% 31 Dec 2021 20-F 30 Mar 2023 2022 FY
Q4 2020 $32,312,000 +$5,024,000 +18% 31 Dec 2020 20-F 24 Mar 2022 2021 FY
Q4 2019 $27,288,000 +$4,357,000 +19% 31 Dec 2019 20-F 25 Mar 2021 2020 FY
Q4 2018 $22,931,000 31 Dec 2018 6-K 01 Jun 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.